TY  - GEN
AU  - Herben,V M
AU  - Panday,V R
AU  - Richel,D J
AU  - Schellens,J H
AU  - van der Vange,N
AU  - Rosing,H
AU  - Beusenberg,F D
AU  - Hearn,S
AU  - Doyle,E
AU  - Beijnen,J H
AU  - ten Bokkel Huinink,W W
TI  - Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer
SN  - 0732-183X
PY  - 1999///0316
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Blood Cell Count
KW  - Cisplatin
KW  - administration & dosage
KW  - Fatigue
KW  - chemically induced
KW  - Female
KW  - Granulocyte Colony-Stimulating Factor
KW  - Humans
KW  - Infusions, Intravenous
KW  - Middle Aged
KW  - Nausea
KW  - Neoplasm Staging
KW  - Neutropenia
KW  - Ovarian Neoplasms
KW  - drug therapy
KW  - Paclitaxel
KW  - Thrombocytopenia
KW  - Topotecan
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.1999.17.3.747
ER  -